GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » FCF Yield %

CARA (Cara Therapeutics) FCF Yield % : -244.10 (As of Apr. 15, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cara Therapeutics's Trailing 12-Month Free Cash Flow is $-61.96 Mil, and Market Cap is $25.38 Mil. Therefore, Cara Therapeutics's FCF Yield % for today is -244.10%.

The historical rank and industry rank for Cara Therapeutics's FCF Yield % or its related term are showing as below:

CARA' s FCF Yield % Range Over the Past 10 Years
Min: -630.15   Med: -13.14   Max: 3.83
Current: -244.1


During the past 13 years, the highest FCF Yield % of Cara Therapeutics was 3.83%. The lowest was -630.15%. And the median was -13.14%.

CARA's FCF Yield % is ranked worse than
93.19% of 1498 companies
in the Biotechnology industry
Industry Median: -15.805 vs CARA: -244.10

Cara Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -277.87%.


Cara Therapeutics FCF Yield % Historical Data

The historical data trend for Cara Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics FCF Yield % Chart

Cara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -9.23 -13.63 -233.34 -221.50

Cara Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -171.65 -251.56 -357.54 -331.09 -57.81

Competitive Comparison of Cara Therapeutics's FCF Yield %

For the Biotechnology subindustry, Cara Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's FCF Yield % falls into.


;
;

Cara Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cara Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-61.963 / 27.97452
=-221.50%

Cara Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-4.043 * 4 / 27.97452
=-57.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cara Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cara Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics Business Description

Traded in Other Exchanges
Address
400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Joana Goncalves officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion officer: Sec'y; Chief Compliance & G.C. C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Menzaghi Frederique Ph.d. officer: VP-Research & Development C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ryan D Maynard officer: Chief Financial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Moltke Lisa Von director C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum director 675 ALMANOR AVE, SUNNYVALE CA 94085
Csl Ltd 10 percent owner
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr director
Thomas Charles Reilly officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd. 10 percent owner RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027